N. Mendoza

发表

Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity

P. Larsen, A. Mirza, J. Hunter, 2010, The Journal of Biological Chemistry.

Unusual Proteolytic Activation of Pro-hepatocyte Growth Factor by Plasma Kallikrein and Coagulation Factor XIa*

D. Kirchhofer, D. Wickramasinghe, N. Mendoza, 2002, The Journal of Biological Chemistry.

556 POSTER MetMAb significantly enhances anti-tumor activity of anti-VEGF and/or erlotinib in several animal tumor models

G. Woude, E. Filvaroff, Zhong Zheng, 2008 .

Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors

J. Zha, G. Woude, M. Romero, 2008 .

Somatic mutations lead to an oncogenic deletion of met in lung cancer.

Somasekar Seshagiri, Jeremy Stinson, S. Seshagiri, 2006, Cancer research.

Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.

R. Schwall, G. Phillips, D. Wickramasinghe, 2002, Cancer research.

Quantitation of TGF-β proteins in mouse tissues shows reciprocal changes in TGF-β1 and TGF-β3 in normal vs neoplastic mammary epithelium

L. Wakefield, K. Flanders, A. Mirza, 2016, Oncotarget.

Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth.

H. Koeppen, R. Schwall, J. Marsters, 2003, Cancer research.

XOMA 052, an anti‐IL‐1β monoclonal antibody, prevents IL‐1β‐mediated insulin resistance in 3T3‐L1 adipocytes

A. Mirza, I. Goldfine, B. Maddux, 2013, Obesity.

Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity

P. Larsen, A. Mirza, J. Hunter, 2010, The Journal of Biological Chemistry.